If you follow the peptide world, you’ve probably seen the headlines this week. Here’s what’s actually confirmed, minus the noise.
On October 14, the FDA submitted a document titled “Interim Access Policy for Compounding Using Certain Peptides” to the White House’s Office of Management and Budget for review. The public listing is short. It’s labeled a notice, it has no legal deadline, and it’s not flagged as economically significant. It doesn’t say which peptides are covered or what the conditions would be.
What we have beyond that comes from reporting. According to CNBC, two people familiar with the plan say it’s meant to let pharmacies temporarily compound some popular peptides, including BPC-157. That would work through “enforcement discretion,” meaning the FDA would choose not to act against pharmacies making them. It wouldn’t be a formal approval. Formally adding peptides to the list of substances that can be compounded would require rulemaking, a process that can take years.
The background matters too. The FDA had previously placed BPC-157 and other injectable peptides on a list of substances it considered too risky to compound, citing possible concerns like contamination. In July, an outside advisory panel recommended easing restrictions on six of the seven peptides it reviewed. The FDA’s own staff scientists said none had been studied enough to establish safety and effectiveness.
So nothing is final yet. And whatever happens, one thing doesn’t change: a label tells you what someone says is in a vial. Testing tells you what’s actually there.
That’s our job. Send us your sample today and verify the contents of your research compounds. We’ll confirm identity by LC-MS and purity by HPLC, and we can add sterility and contamination testing, all on a COA you can verify.
This article is for informational and research purposes only and is not medical or legal advice.